Takeaways

#
  • DePablos favored Pagaya above roughly $33, where the breakout aligned with a previously important price zone.
  • Datadog interested Rosebee as a developing base that still needed confirmation.
  • Affirm's prior breakout and earnings-gap area gave the hosts nearer-term references around $82.
  • They preferred Gilead's stronger structure to Pfizer's position beneath a large topping formation.

Alfonso DePablos finished the September 22, 2025 Chart Request Live with Pagaya as his preferred chart. Riley Rosebee chose Datadog as one he wanted to keep watching.

Their choices did not mean the two stocks were at the same stage. DePablos saw Pagaya moving through a defined breakout area. Rosebee liked the possibility developing in Datadog, but had spent the earlier discussion acknowledging how much work its chart still needed.

Pagaya had a decision point around $33

DePablos examined Pagaya's long-term chart in response to a viewer request. He saw a base forming beneath the large gap left in 2022 and a recovery through a volume-weighted average price anchored to the stock's all-time high.

His reference was approximately $33. Above that area, he thought buyers controlled the trend and the stock had room to work toward the old gap.

He returned to the same zone at the end of the show. The $32 to $33 area had acted as support in 2022 and resistance in 2023. Moving through it therefore connected the current breakout with a level the stock had recognized before.

He also noted substantial short interest as a possible contributor to a squeeze. But the price structure supplied the actual reference: the upper edge of the base and the reclaimed historical level.

Datadog remained a watchlist candidate

Datadog looked less settled. DePablos saw it below its 2021 high and beneath a retracement level that had repeatedly acted as resistance. Several areas of overhead supply still complicated the picture.

He could identify a developing base, but did not consider its existence sufficient reason to participate. He wanted the stock to reclaim an anchored VWAP from a more recent high and get above an area he described as roughly $147 to $150.

Rosebee agreed that the chart could take time. Later, when asked for his favorite request, he selected Datadog precisely as a chart to monitor over the coming weeks and months. He wanted to see how it developed and how many more attempts or shakeouts might precede a breakout.

Affirm showed how a nearer-term reference could help

Affirm offered a third stage of development. DePablos saw a reversal base that had already broken higher and a move above the February peak.

He focused on about $82 as a level he wanted the stock to hold. Rosebee examined the late-August earnings gap and described the surrounding $80 to $85 area as an inflection zone.

An anchored VWAP from that earnings move supplied another short-term reference. The hosts used it to discuss how an investor might evaluate an earlier entry or recognize a possible failed breakout, rather than assume a pullback would arrive on demand.

A cheaper-looking chart was not automatically the better choice

Their healthcare comparison reinforced the distinction. Pfizer remained beneath a large topping formation, and DePablos wanted a recovery through approximately $27 before becoming more interested.

Gilead looked stronger to both hosts. They saw a base pressing toward major highs and a consolidation that DePablos interpreted as buyers absorbing supply near resistance.

Rosebee repeatedly preferred established leaders to stocks whose main attraction was the possibility of catching up. Datadog still earned a place on his watchlist, but the next step remained observable: wait for the developing base to produce the price behavior that the cleaner setups were already showing.

Questions and answers

#

Questions answered in the original 2025-09-22 episode.

Why was $33 important in the Pagaya discussion?

DePablos connected the area with the upper edge of the current base and earlier support and resistance around $32 to $33. He regarded buyers as in control while the stock held above that zone.

Link to this answer

Why did Rosebee choose Datadog after criticizing its chart?

He selected it as a formation to watch, not a completed breakout. He wanted to see how the long-term base evolved over weeks or months, while DePablos identified a reclaim and a move above roughly $147 to $150 as participation conditions.

Link to this answer

What distinguished the Affirm setup?

Its reversal base had already resolved higher. The hosts watched the February peak near $82 and the late-August earnings-gap area, including an anchored VWAP, for a way to evaluate whether the breakout remained intact.

Link to this answer

Adapted by Stock Market TV Editorial from the original video. Source date: . Article published: .